|
|
Principal - Greenwich, Connecticut
|
 |
David Hirsch is a founder and Principal of Longitude Capital. He focuses on investments in biotechnology.
From 2005 to 2006, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy.
He currently serves on the Board of Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals. He is also actively involved with Longitude’s investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM).
Dr. Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a B.A. in Biology from The Johns Hopkins University.
|
|
|
|
